Showing results (441-450 of 472) with videos related to

Sort By:
Pageof 48
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib TherapyJennifer A Woyach, Paolo Ghia, John C Byrd, et al.
Haematologica|January 13, 2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Carcinogenesis|May 29, 2003
Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markersLesley E Rhodes, Hassan Shahbakhti, Richard M Azurdia, et al.
European Heart Journal. Imaging Methods and Practice|August 4, 2026
Hyperaemic effects of adenosine and dobutamine in heart failure with reduced ejection fraction: a quantitative perfusion CMR studySimran Shergill, Ahmed M S E K Abdelaty, Sunny R Sedani, et al.
Neuron|January 30, 2024
Physical and functional convergence of the autism risk genes Scn2a and Ank2 in neocortical pyramidal cell dendritesAndrew D Nelson, Amanda M Catalfio, Julie P Gupta, et al.
Clinical Colorectal Cancer|July 1, 2018
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International RegistryMatthew Burge, Christine Semira, Belinda Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Optics Letters|December 15, 2018
Gas spectroscopy through multimode self-mixing in a double-metal terahertz quantum cascade laserY J Han, J Partington, R Chhantyal-Pun, et al.
Leukemia Research|September 10, 2020
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemiaIsabelle G Solman, Lisa K Blum, Hana Y Hoh, et al.
Blood|July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLLJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Pageof 48